NEWSpublisher 2007 :: AngloChinese Investments
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
from:    to: 
R & D
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Beijing Med-Pharm back to previous page show list

Beijing Med-Pharm

address: Philadelphia:
Beijing Med-Pharm Corp.
600 W. Germantown Pike, Suite 400
Plymouth Meeting, PA 19462
United States of America

Tel: 1-610-940-1675
Fax: 1-610-940-1676
contact: Beijing:
Beijing Med-Pharm Co., Ltd.
1908, Kuntai International Mansion
No.B12 Chaowai Street
Chaoyang District, Beijing 10020
People's Republic of China

Tel: 86-10-5879-7711
Fax: 86-10-5879-7741
key person: David Gao, Chief Executive Officer

madame Zhao (oversees China operations)

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: YES

SFDA approved: NO


Activities engaged in:
Manufacture: NO
Active Pharmaceutical: NO
Ingredients: NO
Western Generics: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: YES

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
Licensed Drugs: NO

Corporate Profile
Beijing Med-Pharm is a Delaware Corporation incorporated in 2003.
Headquartered in suburban Philadelphia, Pennsylvania, and with operations throughout the Peoples Republic of China, Beijing Med-Pharm is focused on becoming the premier development, marketing, and distribution partner for Western manufacturers seeking to introduce high value pharmaceuticals into the large and growing Chinese marketplace.
Complementing seasoned development, sales and marketing teams, Beijing Med-Pharm is building a unique, proprietary network of regional distributors that will allow the Company to reach major Chinese cities comprising the majority of demand for Western medicines. Beijing Med-Pharm is also in-licensing a growing portfolio of branded pharmaceutical products that it will market exclusively across China.
Beijing Med-Pharm offers the following services in China: pre-market entry analysis; clinical trial management; product registration; market research; pharmaceutical distribution to hospitals; and pharmaceutical marketing to physicians, hospitals and other healthcare providers. Beijing Med-Pharm is a Delaware Corporation with Chinese subsidiaries. They are able to offer an end-to-end solution to western pharmaceutical companies interested in selling their products into the Chinese marketplace.
Services include:
Pre-market entry analysis
Clinical trial management
Pre-registration and registration of pharmaceuticals for sale in the People's Republic of China
Market research
Pharmaceutical marketing to physicians, hospitals, and other healthcare providers
Pharmaceutical distribution to hospitals
In December 2004, Beijing Med-Pharm signed an agreement to purchase Beijing Wanwei Pharmaceutical Corporation, Ltd., a pharmaceutical distributor covering the bulk of Beijing's hospitals.
This was a historic event, the first-ever purchase of a Chinese pharmaceutical distribution company by a foreign entity, permitted only after a December 2004 change in Chinese law.
By adding this distributor to their already-existing sales and marketing services, Beijing Med-Pharm hopes to offer an unparalleled opportunity to reach China, the world's fastest-growing market. And their veteran pharmaceutical management staff makes it simple for you to do so. 
Martyn Greenacre, Chairman
Martyn Greenacre has served as Chairman of the Board of Beijing Med-Pharm since July 2004.
Since 2002, Mr. Greenacre has also served as Chairman of Life Mist LLC, a fire suppression equipment company. From 1997 to 2001 Mr. Greenacre served as Chief Executive Officer and director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company. From 1993 to 1997, Mr. Greenacre served as President and Chief Executive Officer of Zynaxis Inc., a biopharmaceutical company. From 1989 to 1992, Mr. Greenacre was Chairman Europe, SmithKline Beecham Pharmaceutical company. Mr. Greenacre joined Smith Kline & French in 1973, where he held positions of increasing responsibility in its European organization.
Mr. Greenacre currently serves as a director of Acusphere, Inc., a drug delivery company, Cephalon Inc., a pharmaceutical company, Curis Inc., a biotechnology company, and Immune Response Corp, a vaccine company.
David Gao, Chief Executive Officer
David (Xiaoying) Gao has served as BMP's President and Chief Executive Officer since February 2004. Since February 2002, Mr. Gao has also served as the Chairman of the board of directors of BMP China. Mr. Gao served as President and director of Abacus, a private wealth management company, from August 2003 until June 2004, and as Chief Executive Officer of Abacus from July 2003 to June 2004.
From 1989 to 2002, Mr. Gao held various positions at Motorola, including: Vice President and Director, Integrated Electronic System Sector, Asia-Pacific operation, from 1998 to 2002; Member, Motorola Asia Pacific Management Board, Management Board of Motorola Japan Ltd., from 2000 to 2002; and Motorola China Management Board from 1996 to 2002.
Mr. Gao holds a BSC in Mechanical Engineering from the Beijing Institute of Technology, a BSC in Mechanical Engineering from Hanover University, Germany, and an M.B.A. from The Massachusetts Institute of Technology.
Fred Powell, Chief Finance Officer
Mr. Powell comes to Beijing Med-Pharm from EXIMIAS Pharmaceutical Corporation, where he served as Chief Financial Officer since 2002.
Prior to joining EXIMIAS, he was Senior Vice President, Finance and Administration at InnaPhase where he was responsible for all financial, internal control, human resources, administrative, and legal matters.
At Premier Research Worldwide (PRWW), a leading contract research organization to the pharmaceutical industry, Mr. Powell was Chief Financial Officer and helped PRWW become one of the nation's leading clinical research organizations by leading the company's initial public offering and managing several acquisitions including DLB (a clinical trial and data management software company).
From 1983 until 1989, Mr. Powell spent seven years at KPMG Peat Marwick as a senior manager responsible for directing the planning, coordination and delivery of audit management and technology services to clients in the pharmaceutical and services industries.
Mr. Powell graduated from Penn State University in 1983 with a Bachelor of Science in Accounting and is a Certified Public Accountant.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.